EP0310542B1
(de)
*
|
1987-10-01 |
1994-06-08 |
Schering Aktiengesellschaft |
Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
|
DE3733478A1
(de)
*
|
1987-10-01 |
1989-04-13 |
Schering Ag |
Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
GB8813353D0
(en)
*
|
1988-06-06 |
1988-07-13 |
Ici Plc |
Therapeutic product
|
US5686465A
(en)
*
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
US5393785A
(en)
*
|
1988-10-31 |
1995-02-28 |
Endorecherche, Inc. |
Therapeutic antiestrogens
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
HU208150B
(en)
*
|
1988-10-31 |
1993-08-30 |
Endorecherche Inc |
Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
|
US5395842A
(en)
*
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
FR2643638B1
(fr)
*
|
1989-02-24 |
1991-06-14 |
Roussel Uclaf |
Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
WO1990010462A1
(en)
*
|
1989-03-10 |
1990-09-20 |
Endorecherche Inc. |
Combination therapy for treatment of estrogen sensitive diseases
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
ATE170753T1
(de)
*
|
1989-07-07 |
1998-09-15 |
Endorecherche Inc |
Androgenderivate zur hemming der aktivität der sexualsteroide
|
JP3350048B2
(ja)
*
|
1989-07-07 |
2002-11-25 |
アンドルシェルシュ・インコーポレイテッド |
アンドロゲン関連疾患の治療方法
|
DE3925507A1
(de)
*
|
1989-07-28 |
1991-01-31 |
Schering Ag |
14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
CZ286894A3
(en)
*
|
1992-05-21 |
1995-09-13 |
Endorecherche Inc |
Pharmaceutical preparation
|
DE19622457A1
(de)
*
|
1996-05-24 |
1997-11-27 |
Schering Ag |
7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US5866560A
(en)
*
|
1996-08-20 |
1999-02-02 |
Schering Ag |
7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
|
DE19635525A1
(de)
*
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
AU1110699A
(en)
*
|
1997-10-23 |
1999-05-10 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7alpha-thioethers
|
US6355630B1
(en)
|
1997-10-23 |
2002-03-12 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7α-thioethers
|
PE20000129A1
(es)
*
|
1997-12-23 |
2000-03-11 |
Schering Ag |
11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
|
DE19807791A1
(de)
|
1998-02-19 |
1999-08-26 |
Schering Ag |
Kombinationspräparat aus Östrogen und Antiöstrogen
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
GB0000313D0
(en)
*
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
DE10027887A1
(de)
*
|
2000-05-31 |
2001-12-13 |
Jenapharm Gmbh |
Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
WO2002002589A1
(fr)
|
2000-06-30 |
2002-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Nouvel agent antiandrogene
|
GB0025221D0
(en)
*
|
2000-10-14 |
2000-11-29 |
Astrazeneca Ab |
New process
|
US20050084908A1
(en)
*
|
2000-11-06 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
|
LT3143995T
(lt)
|
2001-02-19 |
2019-01-25 |
Novartis Ag |
Rapamicino darinys, skirtas plaučių vėžio gydymui
|
ATE359790T1
(de)
|
2001-05-16 |
2007-05-15 |
Novartis Pharma Gmbh |
Kombination von n- 5- 4-(4-methyl-piperazino- methyl)-benzoylamido -2-methylphenyl -4-(3- pyridil)-2pyrimidine-amin mit einem biphosphonat
|
GB0123961D0
(en)
*
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
DE10159217A1
(de)
|
2001-11-27 |
2003-06-05 |
Schering Ag |
17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
EP1944026B1
(de)
|
2002-05-16 |
2013-06-26 |
Novartis AG |
Verwendung von EDG-Rezeptorbindemitteln bei Krebs
|
JP4563171B2
(ja)
*
|
2002-05-24 |
2010-10-13 |
シェーリング コーポレイション |
中和ヒト抗igfr抗体
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
EP2253614B1
(de)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitoren von IAP
|
CN100395259C
(zh)
*
|
2004-04-28 |
2008-06-18 |
江苏豪森药业股份有限公司 |
甾体类衍生物
|
US20050277625A1
(en)
*
|
2004-05-21 |
2005-12-15 |
Ralf Wyrwa |
Estriol and estetrol prodrugs
|
US7534780B2
(en)
*
|
2004-05-21 |
2009-05-19 |
Bayer Schering Pharma Aktiengesellschaft |
Estradiol prodrugs
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
KR20070061526A
(ko)
*
|
2004-07-27 |
2007-06-13 |
시코르, 인크. |
7α-알킬화 19-노르스테로이드의 제조 방법
|
AU2006207325B2
(en)
|
2005-01-21 |
2012-08-16 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
JP4875064B2
(ja)
*
|
2005-04-15 |
2012-02-15 |
シェーリング コーポレイション |
癌を処置または予防するための方法および組成物
|
WO2006116718A2
(en)
|
2005-04-28 |
2006-11-02 |
Proteus Biomedical, Inc. |
Pharma-informatics system
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US9062126B2
(en)
|
2005-09-16 |
2015-06-23 |
Raptor Pharmaceuticals Inc. |
Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
|
KR20080054417A
(ko)
|
2005-09-27 |
2008-06-17 |
노파르티스 아게 |
카르복시아민 화합물 및 hdac 의존성 질환의 치료에있어서의 그의 용도
|
EP1819344A2
(de)
*
|
2005-10-05 |
2007-08-22 |
Sicor, Inc. |
Trennung von fulvestrantisomeren
|
KR20140012218A
(ko)
|
2005-11-21 |
2014-01-29 |
노파르티스 아게 |
Mtor 억제제를 사용하는 신경내분비 종양 치료법
|
US20070197488A1
(en)
*
|
2005-11-29 |
2007-08-23 |
Olaf Peters |
Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
|
US20070123500A1
(en)
*
|
2005-11-29 |
2007-05-31 |
Gerd Mueller |
Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
|
US20070135375A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Sulfamoyl sulfonate prodrugs
|
US20070135399A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Heteroaromatic sulphonamide prodrugs
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
CN102861338A
(zh)
|
2006-04-05 |
2013-01-09 |
诺瓦提斯公司 |
用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
KR20090110913A
(ko)
|
2007-02-15 |
2009-10-23 |
노파르티스 아게 |
Lbh589와 암을 치료하기 위한 다른 치료제와의 조합물
|
WO2009039700A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Xi'an Libang Pharmaceutical Co., Ltd. |
Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentvlsulphinvl) nonvllestra-l,3,5-(10)- triene-3,17-beta-diol
|
US20090082323A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched fulvestrant
|
NZ591955A
(en)
|
2007-10-16 |
2011-10-28 |
Repros Therapeutics Inc |
Trans-clomiphene for diabetes mellitus type 2
|
EP2070941A1
(de)
|
2007-12-14 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Stereoselektive Synthese von selektiven negativen Regulatoren von Östrogenrezeptoren
|
WO2009111057A2
(en)
|
2008-03-07 |
2009-09-11 |
Scidose Llc |
Fulvestrant formulations
|
US8222424B2
(en)
|
2008-03-24 |
2012-07-17 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
AU2009228778B2
(en)
|
2008-03-26 |
2012-04-19 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases B
|
US8063249B1
(en)
|
2008-04-25 |
2011-11-22 |
Olema Pharmaceuticals, Inc. |
Substituted triphenyl butenes
|
WO2010043404A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Synthon B.V. |
Processes and intermediates for the production of fulvestrant
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
JP5564517B2
(ja)
|
2009-02-20 |
2014-07-30 |
ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ |
グルタチオンをベースとする薬物送達システム
|
CN102458374A
(zh)
|
2009-05-06 |
2012-05-16 |
实验室护肤股份有限公司 |
包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
|
EP2258375A1
(de)
|
2009-06-04 |
2010-12-08 |
Bayer Schering Pharma Aktiengesellschaft |
17B-alkyl-17alpha-oxy-estratriene
|
WO2010151133A1
(en)
|
2009-06-25 |
2010-12-29 |
Erasmus University Medical Center Rotterdam |
Methods for establishing and predicting resistance to endocrine therapy using an mirna profile
|
JO2892B1
(en)
|
2009-06-26 |
2015-09-15 |
نوفارتيس ايه جي |
CYP inhibitors 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
IN2012DN01453A
(de)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用
|
CN102596963A
(zh)
|
2009-09-10 |
2012-07-18 |
诺瓦提斯公司 |
二环杂芳基的醚衍生物
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
ES2484171T3
(es)
|
2009-12-08 |
2014-08-11 |
Novartis Ag |
Derivados de sulfonamidas heterocíclicas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
AU2012207142B2
(en)
|
2011-01-20 |
2017-04-27 |
Board Of Regents, The University Of Texas System |
MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
|
EP2673277A1
(de)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
US9029399B2
(en)
|
2011-04-28 |
2015-05-12 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
EP2718276A1
(de)
|
2011-06-09 |
2014-04-16 |
Novartis AG |
Heterocyclische sulfonamidderivate
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
MX2013015001A
(es)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
|
EP2755976B1
(de)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
MD20140054A2
(ro)
|
2011-12-16 |
2014-10-31 |
Olema Pharmaceuticals, Inc. |
Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
|
MY170922A
(en)
|
2011-12-22 |
2019-09-18 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
EA201491264A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
AU2012355615A1
(en)
|
2011-12-23 |
2014-07-10 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
KR20140117457A
(ko)
|
2012-01-31 |
2014-10-07 |
노파르티스 아게 |
Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
|
EP2819676B1
(de)
|
2012-02-29 |
2018-05-30 |
Repros Therapeutics Inc. |
Kombinationstherapie zur behandlung von androgenmangel
|
US11179468B2
(en)
|
2012-04-09 |
2021-11-23 |
Eagle Pharmaceuticals, Inc. |
Fulvestrant formulations
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
EA030698B1
(ru)
|
2012-10-02 |
2018-09-28 |
Эпитерапьютикс Апс |
Ингибиторы деметилаз гистонов
|
JP2016027000A
(ja)
*
|
2012-10-09 |
2016-02-18 |
学校法人早稲田大学 |
ステロイド化合物及びこれを含有する医薬
|
US9315540B2
(en)
|
2012-10-22 |
2016-04-19 |
Intas Pharmaceuticals Ltd. |
Process for the preparation of fulvestrant
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CA2901022C
(en)
|
2013-02-27 |
2021-05-04 |
Epitherapeutics Aps |
Substituted pyridine compounds as inhibitors of histone demethylases
|
US20160060288A1
(en)
*
|
2013-04-18 |
2016-03-03 |
Xi'anlibang Pharmaceutical Technology Co., Ltd. |
Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
EP3046921A4
(de)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituierte aminopyrimidinverbindungen und verfahren zur verwendung
|
BR112016012141A2
(pt)
|
2014-01-15 |
2017-08-08 |
Novartis Ag |
"combinações farmacêuticas, uso das mesmas, e embalagem comercial"
|
WO2015148869A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3126345A1
(de)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitoren von histondemethylasen
|
CN103980336B
(zh)
*
|
2014-05-21 |
2016-10-05 |
天津孚音生物科技发展有限公司 |
一种新的氟维司群的合成方法
|
CN103965280B
(zh)
*
|
2014-05-21 |
2016-04-20 |
天津孚音生物科技发展有限公司 |
一种氟维司群中间体的制备方法
|
WO2015181116A1
(en)
|
2014-05-26 |
2015-12-03 |
Crystal Pharma, S.A.U. |
Process and intermediades for the preparation of 7-alkylated steroids
|
AU2015306662A1
(en)
|
2014-08-27 |
2017-03-09 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
EP3347097B1
(de)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
|
AU2016331065B2
(en)
|
2015-10-01 |
2021-04-29 |
Olema Pharmaceuticals, Inc. |
Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs
|
AU2016352592B2
(en)
|
2015-11-10 |
2023-04-27 |
Paracrine Therapeutics Ab |
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
|
EP3386968A4
(de)
|
2015-12-09 |
2019-09-25 |
The Board of Trustees of the University of Illinois |
Benzothiophenbasierte selektive östrogenrezeptor-herunterregulierende präparate
|
WO2018017410A1
(en)
|
2016-07-22 |
2018-01-25 |
Eli Lilly And Company |
Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
US11602534B2
(en)
|
2017-12-21 |
2023-03-14 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Pyrimidine derivative kinase inhibitors
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021180111A1
(zh)
|
2020-03-10 |
2021-09-16 |
正大天晴药业集团股份有限公司 |
包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
|
IT202100003176A1
(it)
|
2021-02-12 |
2022-08-12 |
Farmabios Spa |
Processo per la preparazione di fulvestrant
|
CN114716496B
(zh)
*
|
2022-04-29 |
2024-04-02 |
香港中文大学(深圳) |
氟维司群衍生物及氟维司群衍生物制备方法和应用
|
CN116535454A
(zh)
*
|
2023-04-28 |
2023-08-04 |
香港中文大学(深圳) |
氟维司群类化合物及其制备方法和应用
|